Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PARSABIV vs SENSIPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium-sensing receptor (Ca SR) agonist; increases the sensitivity of the Ca SR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.
Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.
Secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis
Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Hypercalcemia in patients with parathyroid carcinoma,Severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy
Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.
30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.
Terminal elimination half-life of 3-5 days, supporting once-weekly subcutaneous dosing.
The terminal elimination half-life of cinacalcet is approximately 30 to 40 hours in patients with normal renal function, supporting once-daily dosing. Steady-state concentrations are achieved within 7 days.
Primarily metabolized via amide hydrolysis and oxidation, with involvement of CYP3A4, CYP2D6, and CYP1A2 as minor pathways.
Hepatic via CYP3A4, CYP2D6, CYP1A2; major metabolites are inactive.
Renal: negligible (<2% unchanged); fecal: primary route via biliary elimination of intact drug and metabolites; not dialyzable.
Renal excretion of unchanged drug and metabolites accounts for approximately 84% of the administered dose; fecal excretion accounts for approximately 11%. The primary metabolic pathway is CYP3A4-mediated oxidation, followed by glucuronidation.
Approximately 90-95% bound to albumin.
Cinacalcet is approximately 93 to 97% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 0.29-0.46 L/kg, indicating distribution limited to extracellular fluid.
The volume of distribution is approximately 1000 L (about 14 L/kg in a 70 kg individual), indicating extensive tissue distribution.
Subcutaneous: approximately 50% (range 40-60%).
Oral bioavailability is approximately 20 to 25% due to first-pass metabolism; administration with food increases bioavailability by approximately 50% compared to fasting.
Contraindicated in patients with estimated glomerular filtration rate (e GFR) less than 15 m L/min/1.73 m². No dose adjustment required for e GFR ≥ 15 m L/min/1.73 m².
No dose adjustment required for mild to moderate renal impairment (Cr Cl >= 30 m L/min). Not recommended for patients with severe renal impairment (Cr Cl < 30 m L/min) due to lack of data.
No specific guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C) due to lack of data.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Use with caution in severe hepatic impairment (Child-Pugh Class C) with no specific dose recommendations.
Safety and efficacy not established in pediatric patients; no approved dosing recommendations.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustments recommended; clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed.
No specific dose adjustment; dosing should be based on renal function. Elderly patients may have decreased renal function; monitor serum calcium and i PTH levels closely.
None.
None.
Hypocalcemia,Seizures potentially due to severe hypocalcemia,QT interval prolongation,Gastrointestinal bleeding,Adynamic bone disease
Hypocalcemia: monitor serum calcium, especially during initiation and dose titration,Seizures: risk due to hypocalcemia,QT prolongation: caution in patients with history of QT interval prolongation or on concurrent QT-prolonging drugs,Hypotension: possible during dialysis use,Adynamic bone disease: potential with oversuppression of PTH
Hypocalcemia
Hypocalcemia (serum calcium < 8.4 mg/d L)
No specific food interactions. However, patients should adhere to a renal diet as prescribed, which may include restrictions on phosphorus and calcium intake. Avoid calcium-containing supplements or binders without medical advice due to risk of hypercalcemia.
SENSIPAR should be taken with food or shortly after a meal to enhance absorption. No specific foods are contraindicated, but avoid high-calcium meals immediately before or after dosing as they may reduce absorption. Grapefruit and grapefruit juice may increase cinacalcet levels; avoid concurrent use.
In animal reproduction studies, intravenous etelcalcetide administered to pregnant rats during organogenesis at doses 2.5 times the maximum recommended human dose (MRHD) based on AUC caused increased incidences of fetal skeletal variations and reduced fetal body weight. In rabbits, no adverse fetal effects were observed at doses up to 0.7 times the MRHD. No adequate and well-controlled studies in pregnant women exist. In the first trimester, exposure poses unknown but potential teratogenic risk. During the second and third trimesters, the drug may cause fetal hypocalcemia due to PTH suppression. Use only if potential benefit justifies potential risk.
First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; potential fetal/neonatal hypocalcemia due to maternal calcium-sensing receptor modulation. Risk cannot be excluded.
No data on etelcalcetide presence in human milk, effects on breastfed infants, or milk production. Animal studies show etelcalcetide is present in rat milk. M/P ratio unknown. Because of the potential for serious adverse reactions including hypocalcemia in nursing infants, advise patients not to breastfeed during treatment and for two weeks after the last dose.
No human data on excretion in breast milk; M/P ratio unknown. Potential for serious adverse reactions (e.g., hypocalcemia) in nursing infants; decision to discontinue breastfeeding or drug based on importance of drug to mother.
No specific dosage adjustments are recommended for pregnancy due to lack of pharmacokinetic data in pregnant women. However, because of the potential for hypocalcemia, more frequent monitoring of serum calcium is advised, and dose adjustments may be needed to maintain calcium levels within target range. The effect of pregnancy on etelcalcetide pharmacokinetics is unknown.
No specific dose adjustment guidelines; pharmacokinetics in pregnancy unknown. Monitor serum calcium frequently and adjust dose to maintain target calcium levels. Consider that volume of distribution and clearance may increase, potentially requiring higher doses.
Monitor serum calcium closely; PARSABIV (etelcalcetide) is a calcimimetic that lowers PTH and serum calcium. Initiate only if corrected serum calcium is above the lower limit of normal. Administer intravenously three times per week during hemodialysis. Dose adjustments needed based on serum calcium and PTH levels. Avoid use with other calcimimetics. May cause significant hypocalcemia, especially in patients with adynamic bone disease.
SENSIPAR (cinacalcet) is a calcimimetic used for secondary hyperparathyroidism in CKD on dialysis and for hypercalcemia in parathyroid carcinoma. Monitor serum calcium closely; hypocalcemia is a common adverse effect. Do not initiate if serum calcium is below the lower limit of normal. Administer with food or shortly after a meal to increase absorption. Dose adjustments may be needed with moderate to severe hepatic impairment.
This medication is given intravenously during your dialysis sessions three times a week.,It works by lowering parathyroid hormone (PTH) levels to help manage secondary hyperparathyroidism.,You will need regular blood tests to monitor your calcium and PTH levels.,Report symptoms of low calcium such as muscle cramps, numbness, tingling around the mouth, or seizures.,Do not take any other medications for secondary hyperparathyroidism unless prescribed by your doctor.
Take this medication with food or right after a meal.,Do not split, crush, or chew tablets; swallow whole.,Report symptoms of low calcium: muscle cramps, numbness, tingling, or seizures.,Keep all lab appointments for calcium and PTH monitoring.,Avoid taking with other medications without consulting your doctor; some may interact.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PARSABIV vs SENSIPAR, answered by our medical review team.
PARSABIV is a Calcimimetic that works by Calcium-sensing receptor (Ca SR) agonist; increases the sensitivity of the Ca SR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.. SENSIPAR is a Calcimimetic that works by Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PARSABIV and SENSIPAR depend on the specific clinical indication. These are both Calcimimetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PARSABIV is: Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.. The standard adult dose of SENSIPAR is: 30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PARSABIV and SENSIPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PARSABIV is classified as Category C. In animal reproduction studies, intravenous etelcalcetide administered to pregnant rats during organogenesis at doses 2.5 times the maximum recommended human dose (MRHD) based on A. SENSIPAR is classified as Category C. First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.